DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Rugo HS, Im SA, Cardoso F. et al.
Phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. San Antonio Breast Cancer Symposium 2019.
AACR Cancer Res 2020;
80 (4 Suppl.): Abstract GS1-02
We do not assume any responsibility for the contents of the web pages of other providers.